MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. (MAIA) on November 15, 2023. The filing details a material definitive agreement entered into on the same date regarding a registered direct offering and a concurrent private placement. The company is an emerging growth company incorporated in Delaware and trades on the NYSE American under the symbol "MAIA."
Key Financial Metrics and Transaction Details
- Offering Structure: The company agreed to sell 2,424,243 shares of common stock at $1.65 per share in a registered direct offering.
- Warrants: Concurrently, the company issued unregistered warrants to purchase up to 2,424,243 shares at an exercise price of $1.86 per share. These warrants are exercisable six months after issuance and have a five-year term.
- Gross Proceeds: The company expects to receive approximately $4.0 million in gross proceeds before deducting fees and expenses.
- Placement Agent Fees: H.C. Wainwright & Co., LLC will receive a cash fee of 7.0% of gross proceeds, a management fee of 1.0%, a $35,000 expense allowance, and $50,000 for legal and out-of-pocket expenses. Additionally, Wainwright received warrants to purchase 169,697 shares at $2.0625 per share.
- Stockholders' Equity: As of September 30, 2023, stockholders' equity was approximately $2.7 million. The company anticipates that net proceeds of approximately $3.47 million from this offering will raise equity above the $4.0 million threshold required for continued listing.
Material Changes and Listing Compliance
The primary material change is the capital raise intended to address a compliance issue with the NYSE American. On November 14, 2023, the company was orally advised that it was not in compliance with the continued listing standard requiring stockholders' equity of at least $4 million, given its history of net losses in fiscal years 2020, 2021, and 2022. The filing does not provide comparative financial metrics (revenue, profit, cash flow) for the current period versus prior periods, as this is a transactional filing rather than a periodic financial report.
Outlook, Risks, and Restrictions
- Closing Date: The closing of the offering is expected on or about November 17, 2023, subject to customary conditions.
- Lock-Up Agreements: Directors and executive officers have entered into lock-up agreements prohibiting the sale of securities for 60 days following the closing.
- Issuance Restrictions: For 60 days post-closing, the company is restricted from issuing additional equity or filing new registration statements, with certain exceptions. For one year post-closing, the company is restricted from issuing securities with variable conversion prices or reset features.
- Forward-Looking Statements: The company cautions that the closing is not guaranteed and that the projected increase in stockholders' equity is contingent upon the successful closing of the offering.
Investor Verification Checklist
- Verify the actual closing of the offering and the final net proceeds received.
- Confirm the company's receipt of formal written notice from NYSE American regarding the equity compliance issue and the subsequent reinstatement of listing status.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and warranties.
- Monitor the company's cash burn rate and runway following the capital raise, given the history of net losses.
- Check for any subsequent filings regarding the exercise of warrants or changes in the beneficial ownership limitations.